Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK)

Authors :: Soledad Gallego Melcon
Gilles Vassal
Julia L. Glade Bender
Pooja Hingorani
Nicolas U. Gerber
Gianni Bisogno
Mathew Simcock
Ruta Slepetis
Lucas Moreno
Pablo Berlanga
Carla Manzitti
Isabelle Aerts
Sylvain Baruchel
Ileana Elias
Birgit Geoerger
Julia C. Chisholm
Pascal Chastagner
Michela Casanova
Franca Fagioli
Christophe Bergeron
Source :: Journal of Clinical Oncology. 34:10551-10551
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 10551Background: Although solvent-based paclitaxel has demonstrated activity in adult pts with STs, solvents produce significant neurotoxicity in pediatric pts. nab-P is an albumin–bound paclitaxel...

Tools